Silverio Tomao
A5114430074- Reproductive Biology and Fertility
- Ovarian function and disorders
- Ovarian cancer diagnosis and treatment
- Reproductive Health and Technologies
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- DNA Repair Mechanisms
- Cervical Cancer and HPV Research
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Assisted Reproductive Technology and Twin Pregnancy
- Breast Cancer Treatment Studies
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Metabolism, Diabetes, and Cancer
- Peptidase Inhibition and Analysis
- Colorectal and Anal Carcinomas
- Male Breast Health Studies
- PI3K/AKT/mTOR signaling in cancer
- Gynecological conditions and treatments
- Cutaneous Melanoma Detection and Management
- Chemotherapy-related skin toxicity
Sapienza University of Rome
2011-2022
Policlinico Umberto I
2018-2020
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
2019
Consorzio Interuniversitario per le Biotecnologie
2019
Ospedale Santa Maria Goretti
2013
Instituto Nazionale Tumori Regina Elena
2006
Tumori Foundation
2006
// Patrizia Vici 1 , Laura Pizzuti Andrea Michelotti 2 Isabella Sperduti 3 Clara Natoli 4 Lucia Mentuccia 5 Luigi Di Lauro Domenico Sergi Paolo Marchetti 6 Daniele Santini 7 Emanuela Magnolfi Iezzi Luca Moscetti 8 Agnese Fabbri 9 Alessandra Cassano 10 Antonino Grassadonia Claudia Omarini 11 Federico Piacentini Botticelli Ilaria Bertolini Angelo Fedele Scinto 12 Germano Zampa 13 Maria Mauri 14 Loretta D'Onofrio Valentina Sini Maddalena Barba Marcello Maugeri-Saccà Ernesto Rossi Elisabetta...
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test.Median follow-up, length pertuzumab, trastuzumab maintenance 21, 4 15 months, respectively. The response rate was 77.3%, clinical benefit 93.6%. Median progression-free survival (mPFS) 21 median overall (mOS) not...
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer well established. However, little known in the metastatic setting, especially HER2-positive patients. We assessed influence BMI on clinical outcomes patients treated pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ (mBC). was addressed as categorical variable, being classified basis following ranges, that is, 18.5-24.9, 25-29.9, 30.0-34.9, namely, normal weight, overweight, Class I obesity....
Cancer and coagulation activation are tightly related. The extent to which factors related both these pathologic conditions concur patient prognosis intensely animates the inherent research areas. study herein presented aimed development of a tool for assessment stratification risk death disease recurrence in early breast cancer. Between 2008 2010, two hundreds thirty-five (N: 235) patients diagnosed with stage I–IIA cancer were included. Data on demographics clinic-pathologic features...
Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated a observational study 102 postmenopausal, HR + HER2- metastatic patients treated with everolimus-exemestane first subsequent lines. Best overall response (BR) clinical benefit rate (CBR) assessed across subgroups defined upon fasting (FG) body mass index (BMI). Survival was estimated by Kaplan-Meier method...
Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After accurate assessment the risk/benefit ratio, low-dose estrogen (better with estriol) [corrected] may have role controlling selected informed women.
Currently, no clearly superior management strategy exists for recurrent, platinum-resistant ovarian cancer. We tested the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) in a multicentre phase II clinical trial. Forty one patients cancer were enrolled. Prior to study entry, all participants had received at least platinum-based regimen. Gemcitabine was administered 1000 mg/m2 as protracted infusion (100 min) on day 1, dose 100 2 hour infusion. Cycles repeated every two...
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival first-line (mPFS1) was 12 months. Pertuzumab as conferred longer mPFS1 compared other treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS second-line (mPFS2) 7 no difference subtype,...
Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with various clinical presentations and growth rates. NET incidence has been estimated to 2.5-5 per 100,000 people year, prevalence is 35 100,000. They frequently associated synchronous or metachronous second primary (SPM).We retrospectively reviewed our institutional database on patients. We report 30 patients NETs SPMs from series 262 NETs: 10 (33.3%) 20 (66.6%).The median patient age was 67 years. Of the lesions, 50%...